RadioMedix, Inc. has announced a 5-year agreement with Van Overeem Nuclear B.V. for the supply of 228Th (Thorium-228), enhancing its resources for the development of 212Pb (Lead-212) therapies. This partnership is pivotal for RadioMedix's long-term strategy in Targeted Alpha Therapy (TAT), which aims to improve cancer treatment options. The agreement ensures a steady supply of high-quality 228Th, crucial for expanding RadioMedix's manufacturing capabilities and meeting clinical demands. Both companies express optimism about the role of 212Pb in revolutionizing cancer therapies and advancing nuclear medicine.
Fri, 12 Dec 2025 13:00:00 GMT | GlobeNewswire